Publications by authors named "Donald Negroski"

Claim this Profile
D
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Barry A Singer, Douglas L Arnold, Jelena Drulovic, Mark S Freedman, Ralf Gold, Donald Negroski

Mult Scler· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
Penny Pennington, Bianca Weinstock-Guttman, Channa Kolb, Dejan Jakimovski, Katherine Sacca, Donald Negroski

J Neurol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Regina Berkovich, Donald Negroski, Daniel Wynn, Daniel Sellers, Kristen G Bzdek

Mult Scler Relat Disord· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
Penny Pennington, Bianca Weinstock-Guttman, Channa Kolb, Dejan Jakimovski, Katherine Sacca, Donald Negroski

J Neurol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
Sibyl Wray, Florian Then Bergh, Annette Wundes, Douglas L Arnold, Jelena Drulovic, Donald Negroski

Adv Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis